MetaCap

bioAffinity Technologies Inc. (BIAF)

NASDAQ: BIAFHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD

1.65-0.20 (-10.81%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

BIAF stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$40.37
52-week range
1.63 – 80.70
Day range
1.63 – 1.84
Volume / Avg
52.64K / 3.55M
Beta
—

52-week range

$1.63$80.70

BIAF stock today

Shares of bioAffinity Technologies (BIAF) finished lower on Nov 20 at $1.65, a drop of 10.81% or $0.20 per share, versus the S&P 500's 3.70% decline. Trading was light, with 52.64K shares changing hands, about 1% of the average daily volume. At this level, BIAF sits near the bottom of its 52-week range of $1.63 to $80.70: 98.0% below the high and 1.2% above the low.

bioAffinity Technologies has posted a net loss over the last twelve months (EPS of -$40.37), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About bioAffinity Technologies

Company profile

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services.

Industry
Biotechnology: Commercial Physical & Biological Resarch
CEO
Ms. Maria Zannes J.D.
Headquarters
San Antonio, TX
Employees
57
IPO year
2022

Financial highlights

Full financials

In fiscal 2025, bioAffinity Technologies generated $6.2 million in revenue, down 34.2% from fiscal 2024, the first decline in the 5 years shown. bioAffinity Technologies reported a net loss of $14.9 million, compared with a loss of $9.0 million a year earlier. Operating margin was -171.6%.

bioAffinity Technologies annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$6.16M$9.36M$7.90M$6.90M—
Growth-34.18%+18.51%+14.49%——
Net income$-14.91M$-9.04M$-7.94M$-8.15M$-6.33M
EPS (diluted)$-8.66$-22.50$-0.91$-1.81—

Earnings

Earnings history
Last reported (Sep/2026)
Nov 13, 2026
EPS actual vs est.
$-5.89 vs —

BIAF news

All BIAF news

bioAffinity Technologies peers

Health Care sector
BIAF peer companies
CompanyPrice% ChgMarket capCompare
ISPCiSpecimen Inc.0.4563-13.58%$2.64Mvs BIAF
ONMDOneMedNet Corp Class A4.70+4.21%$29.15Mvs BIAF
MXCTMaxCyte Inc.1.37+7.03%$141.45Mvs BIAF
NRCNRC Health25.16+0.68%$533.93Mvs BIAF
OABIOmniAb Inc.4.66-7.36%$679.71Mvs BIAF
ABSIAbsci Corporation7.51-7.97%$1.30Bvs BIAF
ICLRICON plc186.71-1.92%$13.99Bvs BIAF
CRLCharles River Laboratories International Inc.314.32-4.15%$15.06Bvs BIAF

Indexes, lists and sector

bioAffinity Technologies stock FAQ

What is bioAffinity Technologies's stock price today?

BIAF last traded at $1.65 as of Nov 20, 4:00 PM EST, down 10.81% on the day. Prices are delayed at least 15 minutes.

Who is bioAffinity Technologies's CEO?

Ms. Maria Zannes J.D. is the chief executive officer of bioAffinity Technologies Inc., which has about 57 employees.

What is the BIAF 52-week high?

The 52-week high for BIAF is $80.70 and the 52-week low is $1.63. The stock is currently 98.0% below its high.

Compare BIAF